Ceftriaxone-Induced Hemolytic Anemia: A Rare and Fatal Reaction

Overview

Journal Cureus

Specialty Biomedical Engineering

Date 2024 Jun 4

PMID 38832173

Authors

Michael V DiCaro

Claire Chen

Shawn Wang

Annette Y Eom

Sandhya Wahi-Gururaj

Affiliations

Soon will be listed here.

Abstract

Ceftriaxone, a regularly used antibiotic for broad-spectrum coverage, is a rare cause of hemolytic anemia. Patients may present with truncal pain, nausea, vomiting, and an acute drop in hemoglobin within 48 hours of administration. Prompt recognition and initiation of treatment are essential. We describe a case of a 65-year-old woman being treated for osteomyelitis who developed hemolytic anemia, disseminated intravascular coagulation, and multi-system organ failure after being de-escalated from cefepime to ceftriaxone.

Citing Articles

Ceftriaxone-induced hemolytic anemia managed successfully in a 54-year-old woman: a case report and literature review.

Zhang L, Huang W, Xu J, Li Y, Zhu J Front Pharmacol. 2025; 15():1505366.

PMID: 39840085 PMC: 11747560. DOI: 10.3389/fphar.2024.1505366.

References

Dara R, Sharma R, Bhardwaj H . Severe drug-induced immune hemolysis due to ceftriaxone. Asian J Transfus Sci. 2021; 14(2):187-191. PMC: 7983143. DOI: 10.4103/ajts.AJTS_67_17. View

Karunathilaka H, Chandrasiri D, Ranasinghe P, Ratnamalala V, Fernando A . Co-Amoxiclav Induced Immune Haemolytic Anaemia: A Case Report. Case Rep Hematol. 2020; 2020:9841097. PMC: 7150724. DOI: 10.1155/2020/9841097. View

Northrop M, Agarwal H . Ceftriaxone-induced hemolytic anemia: case report and review of literature. J Pediatr Hematol Oncol. 2014; 37(1):e63-6. DOI: 10.1097/MPH.0000000000000181. View

Kumar S, Bansal R, Bansal P, Dhamija R, Neurology D . Ceftriaxone-Induced Hemolytic Anemia: A Rare Case Report. Perm J. 2020; 24. PMC: 6972626. DOI: 10.7812/TPP/19.088. View

Chaudhry S, Veve M, Wagner J . Cephalosporins: A Focus on Side Chains and β-Lactam Cross-Reactivity. Pharmacy (Basel). 2019; 7(3). PMC: 6789778. DOI: 10.3390/pharmacy7030103. View

Arndt P, Leger R, Garratty G . Serologic characteristics of ceftriaxone antibodies in 25 patients with drug-induced immune hemolytic anemia. Transfusion. 2011; 52(3):602-12. DOI: 10.1111/j.1537-2995.2011.03321.x. View

Mayer B, Bartolmas T, Yurek S, Salama A . Variability of Findings in Drug-Induced Immune Haemolytic Anaemia: Experience over 20 Years in a Single Centre. Transfus Med Hemother. 2015; 42(5):333-9. PMC: 4678312. DOI: 10.1159/000440673. View

Garratty G . Immune hemolytic anemia associated with drug therapy. Blood Rev. 2010; 24(4-5):143-50. DOI: 10.1016/j.blre.2010.06.004. View

DErrico S, Frati P, Zanon M, Valentinuz E, Manetti F, Scopetti M . Cephalosporins' Cross-Reactivity and the High Degree of Required Knowledge. Case Report and Review of the Literature. Antibiotics (Basel). 2020; 9(5). PMC: 7277108. DOI: 10.3390/antibiotics9050209. View

10.

Macy E, Poon K-Y T . Self-reported antibiotic allergy incidence and prevalence: age and sex effects. Am J Med. 2009; 122(8):778.e1-7. DOI: 10.1016/j.amjmed.2009.01.034. View

11.

Leicht H, Weinig E, Mayer B, Viebahn J, Geier A, Rau M . Ceftriaxone-induced hemolytic anemia with severe renal failure: a case report and review of literature. BMC Pharmacol Toxicol. 2018; 19(1):67. PMC: 6203207. DOI: 10.1186/s40360-018-0257-7. View

12.

Sharma A, Chamberlain S, Mannuru D, Matta A . An Uncommon Incidence of Drug-Induced Immune Hemolytic Anemia Secondary to Ceftriaxone. Cureus. 2022; 13(12):e20682. PMC: 8786587. DOI: 10.7759/cureus.20682. View

13.

Pierce A, Nester T . Pathology consultation on drug-induced hemolytic anemia. Am J Clin Pathol. 2011; 136(1):7-12. DOI: 10.1309/AJCPBVLJZH6W6RQM. View